Enhanced Market Penetration of Core Marketed ProductsPipeline Product Uni-PTH is Expected to Launch in 2019
HONG KONG,Aug. 24, 2018 /PRNewswire/ -- A fully integrated biopharmaceutical company -- Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased
Key Accomplishments in 1H2018
During the Period, the Group's marketed products, namely GeneTime®, GeneSoft®, Pinup® and Bokangtai have made steady progress respectively, while solid accomplishments have been achieved for the products in pipeline. The key highlights include:
Other than the above accomplishments at the product level, the Group has also progressed with the strategic collaborations to further widen its value chain as well as product reach.
In 1H2018, the Group recorded a turnover of HK$59.6 million, representing a moderate decrease of approximately 5.3% YoY, from HK$62.9 million in 1H2017. The decrease in turnover was mainly attributable to an unexpected one-off incident, which negatively impacted GeneTime®, as well as a decrease in sales of Pinup® due to mounting pressure from the environment. Gross profit decreased slightly by 1.7% to approximately HK$51.6 million (1H2017: HK$52.5 million). The gross profit margin increased by 3.2 percentage points to 86.6% as compared to 83.4% in the same period last year, as some of the Group's marketed drugs enjoyed limited competitions, which placed the Group at a better position for price negotiation.
During the Period, the Group has continued to expand its sales team by increasing direct sales personnel and through restructuring and re-organization. The Group's goal is to further enlarge its direct sales channel, build solid rapport with more hospitals and adapt to the "two-invoice" system. In addition, significant marketing expenses were invested to promote Bokangtai, the new product that launched in 2017. The result is promising with Bokangtai successfully entered into three new provinces. Moreover, the Group decided to make an one-off expense to minimize any potential impact may have been caused by the incident of GeneTime® mentioned above. Therefore, the selling and distribution expenses increased from HK$27.1 million in 1H2017 to HK$59.5 million in 1H2018, representing an increase of 119.8%. In light of this, the Group recorded a loss of HK$63.2 million during the Period with a basic loss per share of HK$1.02 cents.
For the second half of 2018, the zero price mark-up policy and the provincial tender price cuts, as well as the approaching deadline for chemical generics quality and efficacy consistency will continue to appear as uncertainties for drug manufacturers in the PRC. Moreover, the CFDA issued guidelines relating to the evaluation of consistent quality and efficacy of generics, which apply to domestically-produced and imported generic drugs. Such guideline requires pharmaceutical manufacturers to better allocate and utilize their resources and R&D capability by focusing on compelling product. However, with the sustainable organic growth in some sub-segments like diabetes market and favorable national environment supporting innovation, the Group believes that potential growth opportunities still exist.
Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented "we have pursued the strategy of accelerating the BE of Pinup®, Bokangtai and Acarbose tablets, in view to strengthen our competitiveness in the future. Such move will be posing a higher entry barrier for followers. The BE of Pinup®, Bokangtai is scheduled to be completed in 2020 and 2021, respectively."
Mr. Leung continued, "On the other hand, the Group will also focus on opportunities in fast growing sub-segments, such as the diabetes market. Acarbose tablet, one of the major compounds of ?-Glucosidase inhibitors with limited competitors in China, is the Group's key R&D project in the second half of 2018. Together with Beijing Baiao, the related BE of our Acarbose tablet have been initiated shortly. We are confident that we will be the first batch of manufactures to apply for production approval and the application for marketing is expected to be submitted in the first half of 2019."
Mr. Leung further commented, "We will continue to keep a keen eye on M&A opportunities, aiming to further diversify our geographical coverage in Northeast and Central China, so as to pursue advanced technologies. By fully leveraging on our resources and advantages in the second half of 2018 and beyond, we hope to move ambitiously for greater market penetration. With steady progress being made for our marketed drugs and drugs in the pipeline, the Group will strive to generate the best return to our supportive shareholders."
-- END --
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited, a leading integrated biopharmaceutical company, is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments and innovative drugs addressing the therapeutic areas of diabetes, ophthalmology and dermatology.
Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.
This press release is issued by DLK Advisory Limited for and on behalf of Uni-Bio Science Group Limited and its dedicated WeChat ID is UniBio-IR.
For further information, please contact:
Michelle Shi (firstname.lastname@example.org)Linda Liang (email@example.com)Cathy Wu (firstname.lastname@example.org)Max Lau (email@example.com)Tel: +852 2857 7101Fax: +852 2857 7103
View original content:http://www.prnewswire.com/news-releases/uni-bio-science-group-limited-announces-2018-interim-results-300702126.html
SOURCE Uni-Bio Science Group Limited
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All